Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas

INTRODUCTION: BRAF V600 E mutations have been identified in a subset of patients with primary brain tumors. Combination therapy with BRAF and Mitogen-activated protein kinase (MEK) inhibitors (BRAF/MEKi) targeting sequential steps in the MAPK pathway has replaced BRAFi monotherapy as the standard of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fusco, Michael J., Piña, Yolanda, Macaulay, Robert J., Sahebjam, Solmaz, Forsyth, Peter A., Peguero, Edwin, Walko, Christine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506147/
https://www.ncbi.nlm.nih.gov/pubmed/34620004
http://dx.doi.org/10.1177/10732748211040013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506147/
https://www.ncbi.nlm.nih.gov/pubmed/34620004
http://dx.doi.org/10.1177/10732748211040013

Ejemplares similares